Barron Lindsey, Khadka Subash, Schenken Robert, He Long, Blenis John, Blagg Julian, Chen Shin-Fu, Tsai Kuang-Lei, Boyer Thomas G
Department of Molecular Medicine, University of Texas Health Science Center San Antonio, San Antonio, Texas.
Department of Obstetrics and Gynecology, University of Texas Health Science Center San Antonio, San Antonio, Texas.
F S Sci. 2021 Nov;2(4):383-395. doi: 10.1016/j.xfss.2021.09.003. Epub 2021 Sep 14.
To identify, in myometrial stem/progenitor cells, the presumptive cell of origin for uterine fibroids, substrates of Mediator-associated cyclin dependent kinase 8/19 (CDK8/19), which is known to be disrupted by uterine fibroid driver mutations in Mediator complex subunit 12 (MED12).
Experimental study.
Academic research laboratory.
PATIENT(S): Women undergoing hysterectomy for uterine fibroids.
INTERVENTION(S): Stable isotopic labeling of amino acids in cell culture (SILAC) coupled with chemical inhibition of CDK8/19 and downstream quantitative phosphoproteomics and transcriptomic analyses in myometrial stem/progenitor cells.
MAIN OUTCOME MEASURE(S): High-confidence Mediator kinase substrates identified by SILAC-based quantitative phosphoproteomics were determined using an empirical Bayes analysis and validated orthogonally by in vitro kinase assay featuring reconstituted Mediator kinase modules comprising wild-type or G44D mutant MED12 corresponding to the most frequent uterine fibroid driver mutation in MED12. Mediator kinase-regulated transcripts identified by RNA sequencing were linked to Mediator kinase substrates by computational analyses.
RESULT(S): A total of 296 unique phosphosites in 166 proteins were significantly decreased (≥ twofold) upon CDK8/19 inhibition, including 118 phosphosites in 71 nuclear proteins representing high-confidence Mediator kinase substrates linked to RNA polymerase II transcription, RNA processing and transport, chromatin modification, cytoskeletal architecture, and DNA replication and repair. Orthogonal validation confirmed a subset of these proteins, including Cut Like Homeobox 1 (CUX1) and Forkhead Box K1 (FOXK1), to be direct targets of MED12-dependent CDK8 phosphorylation in a manner abrogated by the most common uterine fibroid driver mutation (G44D) in MED12, implicating these substrates in disease pathogenesis. Transcriptome-wide profiling of Mediator kinase-inhibited myometrial stem/progenitor cells revealed alterations in cell cycle and myogenic gene expression programs to which Mediator kinase substrates could be linked directly. Among these, CUX1 is an established transcriptional regulator of the cell cycle whose corresponding gene on chromosome 7q is the locus for a recurrent breakpoint in uterine fibroids, linking MED12 and Mediator kinase with CUX1 for the first time in uterine fibroid pathogenesis. FOXK1, a transcriptional regulator of myogenic stem cell fate, was found to be coordinately enriched along with kinase, but not core, Mediator subunits in myometrial stem/progenitor cells compared with differentiated uterine smooth muscle cells.
CONCLUSION(S): These studies identify a new catalog of pathologically and biologically relevant Mediator kinase substrates implicated in the pathogenesis of MED12 mutation-positive uterine fibroids, and further uncover a biochemical basis to link Mediator kinase activity with CUX1 and FOXK1 in the regulation of myometrial stem/progenitor cell fate.
在子宫肌层干/祖细胞中鉴定子宫肌瘤可能的起源细胞、中介体相关细胞周期蛋白依赖性激酶8/19(CDK8/19)的底物,已知该激酶在中介体复合物亚基12(MED12)中被子宫肌瘤驱动突变破坏。
实验研究。
学术研究实验室。
因子宫肌瘤接受子宫切除术的女性。
细胞培养中氨基酸的稳定同位素标记(SILAC),联合CDK8/19的化学抑制以及子宫肌层干/祖细胞中的下游定量磷酸化蛋白质组学和转录组学分析。
通过基于SILAC的定量磷酸化蛋白质组学鉴定的高可信度中介体激酶底物,使用经验贝叶斯分析确定,并通过体外激酶测定进行正交验证,该测定以包含野生型或G44D突变体MED12的重组中介体激酶模块为特征,G44D突变体对应于MED12中最常见的子宫肌瘤驱动突变。通过RNA测序鉴定的中介体激酶调节的转录本通过计算分析与中介体激酶底物相关联。
CDK8/19抑制后,166种蛋白质中的总共296个独特磷酸位点显著减少(≥两倍),包括71种核蛋白中的118个磷酸位点,代表与RNA聚合酶II转录、RNA加工和转运、染色质修饰、细胞骨架结构以及DNA复制和修复相关的高可信度中介体激酶底物。正交验证证实了这些蛋白质的一个子集,包括类Cut同源框1(CUX1)和叉头框K1(FOXK1),是以MED12中最常见的子宫肌瘤驱动突变(G44D)消除的方式成为MED12依赖性CDK8磷酸化的直接靶点,表明这些底物参与疾病发病机制。中介体激酶抑制的子宫肌层干/祖细胞的全转录组分析揭示了细胞周期和肌生成基因表达程序的改变,中介体激酶底物可直接与之相关联。其中,CUX1是细胞周期的既定转录调节因子,其在7号染色体q上的相应基因是子宫肌瘤中反复出现断点的位点,首次在子宫肌瘤发病机制中将MED12和中介体激酶与CUX1联系起来。FOXK1是肌生成干细胞命运的转录调节因子,与分化的子宫平滑肌细胞相比,在子宫肌层干/祖细胞中与激酶而非核心中介体亚基协同富集。
这些研究确定了与MED12突变阳性子宫肌瘤发病机制相关的病理和生物学相关中介体激酶底物的新目录,并进一步揭示了在子宫肌层干/祖细胞命运调节中将中介体激酶活性与CUX1和FOXK1联系起来的生化基础。